

Sensitivity Analyses — Inclusion of the BOSON Study Data

TABLE 171: NAIVE GENOTYPE 3

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF24 + RBV24	PR 48	1.30 (1.21 to 1.37)	21.63 (14.70 to 25.93)
DCV12 + SOF12		1.36 (1.26 to 1.41)	25.98 (18.94 to 29.02)
SOF12 + PR12		1.36 (1.22 to 1.41)	25.51 (15.96 to 28.65)
DCV12 + SOF12	SOF24 + RBV24	1.05 (0.96 to 1.13)	4.16 (−3.40 to 11.34)
SOF12 + PR12		1.04 (0.96 to 1.10)	3.58 (−3.33 to 8.99)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF12 + PR12	DCV12 + SOF12	1.00 (0.90 to 1.07)	-0.48 (-9.66 to 6.54)
Random effect model	Residual deviance	7.427 vs. 8 data points	
	Deviance information criteria	52.582	
Fixed effect model	Residual deviance	7.417 vs. 8 data points	
	Deviance information criteria	52.359	

Cri = credible interval; DCV = daclatasvir; PR = pegylated interferon plus ribavirin; RBV = ribavirin; RD = risk difference; RR = relative risk; SOF = sofosbuvir; SVR = sustained virologic response; vs. = versus.
 Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.